S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:AADI

Aadi Bioscience Stock Forecast, Price & News

$19.32
-0.73 (-3.64%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.75
$20.49
50-Day Range
$20.05
$28.46
52-Week Range
$14.31
$49.80
Volume
62,268 shs
Average Volume
277,499 shs
Market Capitalization
$403.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.45
30 days | 90 days | 365 days | Advanced Chart
Receive AADI News and Ratings via Email

Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter.


Aadi Bioscience logo

About Aadi Bioscience

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in October, 2011 and is headquartered in Los Angeles, CA.

Headlines

What 4 Analyst Ratings Have To Say About Aadi Bioscience
November 24, 2021 |  markets.businessinsider.com
Aadi Bioscience Announces FDA Approval Of FYARRO
November 23, 2021 |  benzinga.com
Aadi Gets FDA Approval For FYARRO To Treat Advanced Malignant PEComa
November 23, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AADI
Fax
N/A
Employees
12
Year Founded
N/A

Sales & Book Value

Annual Sales
$15 million
Book Value
$13.70 per share

Profitability

Net Income
$-4.32 million
Pretax Margin
-32.25%

Debt

Price-To-Earnings

Miscellaneous

Free Float
19,411,000
Market Cap
$403.67 million
Optionable
Not Optionable

Company Calendar

Last Earnings
8/10/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

932nd out of 1,390 stocks

Pharmaceutical Preparations Industry

440th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Aadi Bioscience (NASDAQ:AADI) Frequently Asked Questions

Is Aadi Bioscience a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aadi Bioscience stock.
View analyst ratings for Aadi Bioscience
or view top-rated stocks.

How has Aadi Bioscience's stock price been impacted by COVID-19?

Aadi Bioscience's stock was trading at $4.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AADI stock has increased by 377.0% and is now trading at $19.32.
View which stocks have been most impacted by COVID-19
.

When is Aadi Bioscience's next earnings date?

Aadi Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Aadi Bioscience
.

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience Inc (NASDAQ:AADI) announced its earnings results on Tuesday, August, 10th. The company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($3.00) by $2.33.
View Aadi Bioscience's earnings history
.

When did Aadi Bioscience's stock split? How did Aadi Bioscience's stock split work?

Aadi Bioscience's stock reverse split before market open on Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of Aadi Bioscience stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for AADI?

5 brokers have issued 12 month price objectives for Aadi Bioscience's shares. Their forecasts range from $30.00 to $51.00. On average, they expect Aadi Bioscience's stock price to reach $43.75 in the next twelve months. This suggests a possible upside of 126.4% from the stock's current price.
View analysts' price targets for Aadi Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Aadi Bioscience's key executives?

Aadi Bioscience's management team includes the following people:
  • Neil P. Desai, President, CEO, Secretary & Director
  • Brendan Delaney, Chief Operating Officer
  • Lance E. Thibault, Chief Financial Officer
  • Loretta M. Itri, Chief Medical Officer
  • Andrew Kwon, Senior Director-Business Development & Strategy

What is Aadi Bioscience's stock symbol?

Aadi Bioscience trades on the NASDAQ under the ticker symbol "AADI."

Who are Aadi Bioscience's major shareholders?

Aadi Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include VR Adviser LLC (48.11%), BVF Inc. IL (36.08%), Rock Springs Capital Management LP (24.05%), RTW Investments LP (24.05%), RA Capital Management L.P. (10.94%) and Renaissance Technologies LLC (5.21%). Company insiders that own Aadi Bioscience stock include Caley Castelein and Orbimed Advisors Llc.
View institutional ownership trends for Aadi Bioscience
.

Which institutional investors are buying Aadi Bioscience stock?

AADI stock was acquired by a variety of institutional investors in the last quarter, including VR Adviser LLC, BVF Inc. IL, RTW Investments LP, Rock Springs Capital Management LP, RA Capital Management L.P., Renaissance Technologies LLC, Citadel Advisors LLC, and Opaleye Management Inc..
View insider buying and selling activity for Aadi Bioscience
or or view top insider-buying stocks.

How do I buy shares of Aadi Bioscience?

Shares of AADI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aadi Bioscience's stock price today?

One share of AADI stock can currently be purchased for approximately $19.32.

How much money does Aadi Bioscience make?

Aadi Bioscience has a market capitalization of $403.67 million and generates $15 million in revenue each year. The company earns $-4.32 million in net income (profit) each year or ($13.3679) on an earnings per share basis.

How many employees does Aadi Bioscience have?

Aadi Bioscience employs 12 workers across the globe.

What is Aadi Bioscience's official website?

The official website for Aadi Bioscience is www.aerpio.com.

Where are Aadi Bioscience's headquarters?

Aadi Bioscience is headquartered at 9987 Carver Rd, Blue Ash, Ohio 45242-5550.

How can I contact Aadi Bioscience?

Aadi Bioscience's mailing address is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. The company can be reached via phone at (513) 985-1920 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.